Navigation Links
BZL101 in Medical News

Bionovo to Present at Wall Street Analyst Forum's 20th Annual Institutional Investor Conference

...d or currently on the market. bzl101 and other Cancer Drug Candidates ...the powerful and selective mechanism of action for bzl101 in cancer tumors. Another study was presen...8. Results from a second clinical study of bzl101 in advanced breast cancer was presented at ASCO, i...

Bionovo Announces Presentation at the National Cancer Institute

...o be leaders in their markets. Bionovo's clinical pipeline of drug candidates includes Menerba (MF101) for the treatment of menopausal hot flashes and bzl101 for the treatment of advanced breast cancer. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the s...

Bionovo Announces Cost Control Measures Taken

...o be leaders in their markets. Bionovo's clinical pipeline of drug candidates includes Menerba (MF101) for the treatment of menopausal hot flashes and bzl101 for the treatment of advanced breast cancer. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the s...

Bionovo Announces 2007 Financial Results and Highlights

...er Research (AACR). The presentation described how bzl101 elicits its cytotoxic activity on cancer cel... patients into a Phase 1/2 clinical trial of bzl101 for the treatment of advanced breast cancer, after presenting positive Phase 1 findings of bzl101 at the American Association of Cancer Resear...
BZL101 in Medical Technology

Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology

EMERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology's Fifth Internationa...

Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer

EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced today that its drug candidate for metastatic breast cancer, BZL101, will advance to Phase 2 clinical testing after the successful completion of a second Phase 1 clinical trial. The Phase 1B clinical...

Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles

- Results Presented at American Society of Clinical Oncology 44TH Annual Meeting - EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI ) today announced results from a second ongoing clinical trial of BZL101, an oral drug candidate, in...

Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101

BZL101 selectively kills cancer cells but not normal cells EMERYVILLE, Calif., April 1 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI ) today announced the publication of a peer-reviewed article in the journal Cancer Biology and Therapy that elucidates the molecular mechanisms un...

Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial

...es of its innovative breast cancer drug candidate, bzl101 were well tolerated. As a result, the company will... available efficacy information." About BZL101 bzl101 is an oral drug designed for the treatment of adva...argely on glycolysis (>85%) for energy production. bzl101 leads to energy collapse in cancer cells by inhibi...

Bionovo to Present Recent Findings of BZL101, Its Anti-cancer Agent, at the American Association of Cancer Research

... for cancer cell apoptosis (cell death) induced by bzl101 while leaving normal cells unaffected. As explaine...ctor of Cancer Research at Bionovo, the ability of bzl101 to induce apoptosis is due to attenuation of mitoc... of life conditions associated with menopause, and bzl101 is in Phase 1/2 for the treatment of advanced brea...

Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial

...men's health. The company has two drugs in clinical testing. MF101 has completed Phase 2 for quality of life conditions associated with menopause, and bzl101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancrea...
BZL101 in Biological Technology

Bionovo Announces 2008 Highlights and Year-End Financial Results

...d or currently on the market. bzl101 and other Cancer Drug Candidates ...the powerful and selective mechanism of action for bzl101 in cancer tumors. Another study was presen...8. Results from a second clinical study of bzl101 in advanced breast cancer was presented at ASCO, i...

Bionovo Reports Third Quarter 2008 Financial Results

... of advanced breast cancer, menopausal hot flashes, and menopausal vaginal atrophy. Recent advances have included: -- The Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer has now been completed successfully, showing positive safety and tolerabil...

Bionovo Reports Second Quarter 2008 Financial Results

...rence of $4.6 million. Company Highlights -- The Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer continues su...al trials for both MF101 and VG101." "We are very excited at the progress bzl101 is making in the clinical trials for advanced breast cancer. This drug cand...

Bionovo Reports First Quarter 2008 Financial Results

...th $33.3 million, a difference of $3.9 million. Company Highlights -- Patient enrollment and dosing continues in the Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer. Presentations, papers and scientific discussions have expounded the mechanis...

Bionovo Announces Third Quarter 2007 Financial Results

...dosing continues in the Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer. -- Bionovo presented data on bzl101 at the AACR-NCI-EORTC International Conference...r Targets and Cancer Therapeutics showing that bzl101 selectively elicits its cytotoxic activity on canc...
Other Tags
(Date:11/26/2014)... 27, 2014 AlignLife, a chiropractic ... the kick-off of its annual Toy Drive. With ... go to donate to those in need throughout ... organizations to distribute the donations to those most ... locations will be accepting donations at the clinics ...
(Date:11/26/2014)... November 26, 2014 Healthpointe is proud ... Perris , and it will be led by ... in the field of Occupational Medicine and utilizes the ... Medicine specialist delivers quality care for employers and their ... health. , As an Occupational Medicine ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Dr. Parsa ... themselves this holiday season! With Parsa Mohebi Hair Restoration’s ... off of their next FUE procedure, making it that ... FUE—which stands for “Follicular Unit Extraction”—is an advanced variety ... traditional “strip” Follicular Unit Transplantation (FUT). FUE, unlike FUT, ...
(Date:11/26/2014)... 2014 Recently, DressVe , the ... dresses, has unveiled its 2014 Cyber Monday Sales. Also, ... dresses, up to 90 percent off. The special offer ... Free delivery is provided for orders above $69. , ... shoes, handbags and other fashion accessories. The mission of ...
(Date:11/26/2014)... November 27, 2014 Recently, Locks-Magnetic.com, a ... new collection of magnetic locks on the Internet. It ... lasts until December. , As a leading company ... platform for worldwide customers to buy high quality locks. ... more, it provides locks that are not only useful ...
Breaking Medicine News(10 mins):Health News:Healthpointe now offering Occupational Medicine in their Perris Medical Clinic 2Health News:Healthpointe now offering Occupational Medicine in their Perris Medical Clinic 3Health News:FUE Special at Parsa Mohebi Hair Restoration This Holiday Season 2Health News:DressVe.com: Best 2014 Special Monday Sales Online 2Health News:Fresh Products Launched by Famous Company Lock-Magnetic.com 2
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
(Date:11/21/2014)... Nov. 20, 2014 Strict laws against distracted ... piloting the North American and European automotive sector towards ... gesture recognition systems that are intuitive and able to ... the industry. New analysis from Frost ... Market in Europe and ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
Other Contents